FINWIRES · TerminalLIVE
FINWIRES

Clinuvel Unlikely to Seek Scenesse's Vitiligo Approval Before Phase 3 Completion, Says Jefferies

-- Clinuvel Pharmaceuticals (ASX:CUV) is unlikely to seek regulatory approval for Scenesse in vitiligo until the Phase 3 CUV105 and CUV107 clinical trials are completed, according to a Friday Jefferies note.

The company said on Friday that the European Medicines Agency (EMA) has proposed evaluating the company's Scenesse drug for the treatment of systemic vitiligo based on a "totality of evidence" regulatory approach.

Jefferies said that the EMA's decision is a positive for the company because of the high unmet medical need for Vitiligo treatment.

The investment firm has pushed back its revenue expectations from Scenesse in vitiligo, which is now expected to begin in the second half of fiscal 2029 rather than fiscal 2028.

Jefferies kept a buy rating on Clinuvel and cut its price target to AU$39.20 from AU$40.50.

Related Articles

Asia

Hunan Gold Q1 Profit Up 79%, Revenue Climbs 44%

Hunan Gold (SHE:002155) posted first-quarter attributable net profit of 595.5 million yuan, up 79% from 332.3 million yuan the previous year.Earnings per share went up to 0.38 yuan from 0.21 yuan, according to a weekend filing with the Shenzhen bourse.Operating revenue climbed 44% year over year to 18.8 billion yuan from 13.1 billion yuan.Shares of the miner declined 2% in recent trade.

$SHE:002155
International

Singapore Manufacturing Output Rises 10% in March

Singapore's manufacturing output jumped 10.1% in March, backed by strong growth across almost all clusters, the city-state's Department of Statistics reported Monday.Excluding biomedical manufacturing, output rose 13.5% year-on-year in March.Electronics output grew 30%, driven by robust AI-related demand, the data showed. Precision engineering gained 14.0%, while general manufacturing and transport engineering expanded 7.6% and 2.0%, respectively.Meanwhile, biomedical manufacturing fell 14.3%, mainly due to softer demand for medical devices, while chemicals dropped 16.0%.On a month-on-month basis, manufacturing output increased 4.7% in March. Excluding biomedical manufacturing, output was up 3.5% on a monthly basis.

$^STI
Asia

G8 Education Says Macquarie Group Becomes Substantial Holder

G8 Education (ASX:GEM) said Macquarie Group (ASX:MQG) became a substantial holder on April 22 after acquiring 39.2 million securities of the firm, according to a Monday Australian bourse filing.Macquarie's voting power in the firm is now 5.08%.Its shares were up over 1% in recent trading on Monday.

$ASX:GEM$ASX:MQG